AL-S Pharma created to develop innovative therapy for ALS

Switzerland’s Neurimmune and TVM Capital Life Science have joined forces create and fund a single-asset biotech firm focused on amyotrophic lateral sclerosis (ALS).

AL-S Pharma, a company based in Schlieren/Zurich, Switzerland, will develop, to proof-of-concept, AP-101, a human monoclonal antibody targeting misfolded SOD1 for the treatment of amyotrophic lateral sclerosis (ALS) that was generated and pre-clinically validated by Neurimmune’s Reverse Translational Medicine platform. To date, no disease-modifying treatment is available for ALS.

“We are very excited to see another monoclonal antibody developed through our Reverse Translational Medicine platform moving towards clinical development,” says Jan Grimm, chief scientific officer of Neurimmune and member of the board of AL-S Pharma. “ALS is a terrible disease, and we believe that AP-101 has the potential to provide therapeutic benefit to the patients suffering from it.”